Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
The collaboration marks the first time the two companies will co-fund development of a Boston Scientific product.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarction cardiogenic shock (AMI-CS), a life-threatening medical emergency where the heart cannot pump enough blood to supply the brain and other organs with oxygen. This is the first time that Boston Scientific and BXLS will co-fund the development of a Boston Scientific product.
Cardiogenic shock, caused by heart attack or other heart issues, is associated with significant mortality despite advances in treatment. The VITALYST system is being developed to address the core unmet needs of these critically ill patients, with the goal of improving efficacy, safety, and ease of use for the physicians treating them.
“Boston Scientific has built a leading cardiovascular franchise, with deep expertise in developing and commercializing transformative technologies for patients and physicians,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences. “We believe the VITALYST system has the potential to improve on the efficacy and safety of currently available mechanical circulatory support technologies, and this collaboration reflects our ability to help leaders in innovation bring important new medical devices to patients.”
About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $18 billion in assets under management.
Acute myocardial infarction, commonly called a heart attack, happens when blood flow to part of the heart is suddenly blocked, causing heart muscle to be damaged or die; think of it as a plumbing clog that starves part of the heart of oxygen. Investors care because such events drive demand for emergency treatment, long‑term medications, medical devices and hospital services, affect healthcare costs and reimbursement patterns, and can influence the financial outlook and regulatory scrutiny of companies in pharmaceuticals, medical devices and health services.
cardiogenic shockmedical
Cardiogenic shock is a life-threatening condition in which the heart suddenly cannot pump enough blood to meet the body’s needs, causing organ failure and very low blood pressure. Investors watch it because its incidence, treatment options, and survival rates affect demand for medical devices, drugs, hospital resources and clinical-trial outcomes; a new therapy or safety concern tied to cardiogenic shock can materially change a healthcare company’s revenue and regulatory risk.
cardiac outputmedical
The amount of blood the heart pumps each minute, expressed as a volume that reflects how well the heart is delivering oxygen and nutrients to the body. Think of it like how many liters a water pump moves per minute: higher or more efficient flow usually means better heart performance, while lower flow can indicate disease or stress. Investors care because changes in cardiac output are key measurements in drug and device trials, hospital care needs, and potential market demand for treatments that affect heart function.
percutaneousmedical
Percutaneous describes medical procedures or delivery methods that reach internal organs or tissues by passing through the skin — for example with needles, catheters or small tubes — instead of opening the body with large incisions. For investors it matters because percutaneous approaches are generally less invasive, often mean lower hospital time, quicker recovery and smaller device footprints, which can broaden market adoption and affect regulatory and reimbursement outlooks.
